

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM536774

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Abzena (UK) Limited (f/k/a Polytherics Limited)		08/15/2019	Private Company Limited By Shares: UNITED KINGDOM
Abzena (Cambridge) Limited		08/15/2019	Private Company Limited By Shares: UNITED KINGDOM
RECEIVING PARTY DATA			
Name:	Oxford Finance LLC, as Collateral Agent and as a Lender		
Street Address:	133 NORTH FAIRFAX STREET		
City:	ALEXANDRIA		
State/Country:	VIRGINIA		
Postal Code:	22314		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	5093688	EPISCREEN	
Registration Number:	4737716	ABZENA	
Registration Number:	4860075	THIOBRIDGE	
Registration Number:	4438343	CHEMO ASSEMBLY	
Registration Number:	3949768	THERAPEG	
CORRESPONDENCE DATA			
Fax Number:	6785532602		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	67855323601		
Email:	jimmarl@gtlaw.com		
Correspondent Name:	LaShana C. Jimmar, Paralegal		
Address Line 1:	GREENBERG TRAURIG, LLP		
Address Line 2:	3333 PIEDMONT ROAD, NE, SUITE 2500		
Address Line 4:	Atlanta, GEORGIA 30305		
ATTORNEY DOCKET NUMBER:	138179.017500		
NAME OF SUBMITTER:	LaShana C. Jimmar		

CH \$140.00 5093688

SIGNATURE:	/LaShana C. Jimmar/
DATE SIGNED:	08/15/2019
Total Attachments: 21 source=Intellectual Property Security Agreement - Abzena#page1.tif source=Intellectual Property Security Agreement - Abzena#page2.tif source=Intellectual Property Security Agreement - Abzena#page3.tif source=Intellectual Property Security Agreement - Abzena#page4.tif source=Intellectual Property Security Agreement - Abzena#page5.tif source=Intellectual Property Security Agreement - Abzena#page6.tif source=Intellectual Property Security Agreement - Abzena#page7.tif source=Intellectual Property Security Agreement - Abzena#page8.tif source=Intellectual Property Security Agreement - Abzena#page9.tif source=Intellectual Property Security Agreement - Abzena#page10.tif source=Intellectual Property Security Agreement - Abzena#page11.tif source=Intellectual Property Security Agreement - Abzena#page12.tif source=Intellectual Property Security Agreement - Abzena#page13.tif source=Intellectual Property Security Agreement - Abzena#page14.tif source=Intellectual Property Security Agreement - Abzena#page15.tif source=Intellectual Property Security Agreement - Abzena#page16.tif source=Intellectual Property Security Agreement - Abzena#page17.tif source=Intellectual Property Security Agreement - Abzena#page18.tif source=Intellectual Property Security Agreement - Abzena#page19.tif source=Intellectual Property Security Agreement - Abzena#page20.tif source=Intellectual Property Security Agreement - Abzena#page21.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (the “**Intellectual Property Security Agreement**”) is entered into as of August 15, 2019, by and among **OXFORD FINANCE LLC**, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “**Lender**” and collectively, the “**Lenders**”), and **Abzena (UK) Limited** (f/k/a Polytherics Limited), an English private company limited by shares and **Abzena (Cambridge) Limited**, an English private company limited by shares (the “**Grantor**”).

RECITALS

WHEREAS, Lenders agreed to make certain advances of money and to extend certain financial accommodations to (i) **ABZENA (SAN DIEGO) INC**, a California corporation with an office located at 8810 Rehco Road, Suite E, San Diego, CA 92121 (“**SD Borrower**”) and (ii) **ABZENA (BRISTOL) LLC**, a Delaware limited liability company with an office located at 360 George Patterson Blvd., Suite 101E, Bristol PA 19007 (“**DE Borrower**”, and together with SD Borrower, “**Borrower**”) (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among Collateral Agent, Lenders and Borrower dated as of the date hereof (as the same may be, and may have been, amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). In accordance with the terms of the Loan Agreement, Grantor is granting to Collateral Agent, for the ratable benefit of the Lenders, and to each Lender a security interest in, among other things, certain Copyrights, Trademarks, Patents and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, among other things, effective as of the date hereof, Grantor hereby grants and pledges to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Grantor hereby represents and warrants that the Copyrights set forth on Exhibit A, the Patents set forth on Exhibit B and the Trademarks set forth on Exhibit C include all Copyrights, Patents and Trademarks of Grantor that are either registered, or for which applications for registration or grant, as applicable, are pending, on the date hereof. Grantor hereby covenants to provide prompt notice of (A) any material change in the composition of the Intellectual Property, and (B) any new the Copyrights, Trademarks, Patents or Mask Works of Grantor that are either registered or for which an application for registration or grant is filed.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the ratable benefit of the Lenders, under the Loan Agreement and the other Loan Documents, and shall become effective upon the date hereof. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Collateral Agent, of any or all other rights, powers or remedies.

Upon the termination of the Loan Agreement in accordance with its terms and fulfillment of all payment Obligations of Borrower under the Loan Documents, Collateral Agent shall execute,

acknowledge, and deliver to Grantor an instrument in writing in recordable form releasing the collateral pledge, grant, lien and security interest in the Intellectual Property Collateral under this Intellectual Property Security Agreement.

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

FOR AND ON BEHALF OF:

Address of Grantor:

Building 900, Babraham Research Campus
Babraham, Cambridge, CB22 3AT
United Kingdom
Attn: Richard Milbank
Richard.Milbank@abzena.com

ABZENA (UK) LIMITED (f/k/a Polytherics Limited)

By: 

Name: Richard Milbank

Title: Authorised Signatory

Address of Grantor:

Building 900, Babraham Research Campus
Babraham, Cambridge, CB22 3AT
United Kingdom
Attn: Richard Milbank
Richard.Milbank@abzena.com

FOR AND ON BEHALF OF:

ABZENA (CAMBRIDGE) LIMITED

By: 

Name: Richard Milbank

Title: Authorised Signatory

[Signature Page to Intellectual Property Security Agreement]

TRADEMARK
REEL: 006721 FRAME: 0452

LENDER AND COLLATERAL AGENT:

Address of Lender and Collateral Agent:

133 North Fairfax Street
Alexandria, Virginia 22314
Attn: Legal Department

**OXFORD FINANCE LLC, AS
COLLATERAL AGENT AND AS A LENDER**

By: 

Name: Colette H. Featherly

Title: Senior Vice President

EXHIBIT A

Copyrights

None.

EXHIBIT B
Patents

Abzena (UK) Limited

Technology Name	Title	Authority	Legal Status (Standardized)	Current Assignee	Application Number	Application/ Filing Date	Publication Number	Publication Date	Holder of Unreleased Licenses	Notes/Chain of Title Issues	Priority Number(s)	Priority Date(s)	Child Cases
ABZ36	Anti-PSNMA Antibody (Licensed Product)	US	Pending	ABZENA (UK) LIMITED BABR AHAM RESEARCH CAMPUS, BABR AHAM CAMBRIDGE, UNITED KINGDOM CB22 3A	PCT/GB201 7/052448	2017-08-18	WO 2018/0337 49 A1	2018-02-22			1614162.4	2016-08-18	
ABZ33 WO 2017178828 (A1)	Cyclic PEG ADCs	US	Pending	ABZENA (UK) LIMITED BABR AHAM RESEARCH CAMPUS, BABR AHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	PCT/GB201 7/051044	2017-04-13	WO 2017 /178828 A1	2017-10-19			GB1606543.5	2017-04-14	
ABZ35 WO2018051109 (A1)	Novel Cytotoxic Agents And Conjugates Thereof	US	Pending	ABZENA (UK) LIMITED BABR AHAM RESEARCH CAMPUS, BABR AHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US16332797	2017-09-15	US20190202839A1	2019-07-04			GB1615725	2016-09-15	
ABZ28 WO2017212250 (A1)	Antibodies Uses Thereof and Conjugates Thereof	US	Pending	ABZENA (UK) LIMITED BABR AHAM RESEARCH CAMPUS, BABR AHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US16303596	2017-06-06	US20190144562A1	2019-05-16			GB1609866	2016-06-06	

Technology Name	Title	Authority	Legal Status (Standardized)	Current Assignee	Application Number	Application/ Filing Date	Publication Number	Publication Date	Holder of Unreleased Claims	Notes/Chain of Title Issues	Priority Number(s)	Priority Date(s)	Child Cases
ABZ31 WO2017199046 (A1)	Conjugates and Conjugating Reagents	US	Pending	ABZENA (UK) LIMITED BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US16097864	2017-05-19	US20170134220A1	2019-05-09			GB1608936	2016-05-20	
ABZ21 WO2016059377A1	Process For The Conjugation Of A Peptide Or Protein With A Reagent Comprising A Leaving Group Including A Portion Of PEG	US	Pending	ABZENA (UK) LIMITED BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US15517971	2015-10-08	US20170304461A1	2017-10-26			GB1418186	2014-10-14	
ABZ3 WO2016063006 (A1)	Conjugates And Conjugating Reagents	US	Pending	ABZENA (UK) LIMITED BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US15517969	2015-10-08	US20170290925A1	2017-10-12			GB1418984	2014-10-24	
ABZ16 granted US only	Novel Conjugation Reagents	US	Granted: 4th year fee due 07-08-2022	ABZENA (UK) LIMITED BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US15482033	2017-04-07	US20170209589A1	2017-07-27			US61661300	2012-06-18	
ABZ12 (CI process) US Divisional To be abandoned in due course	Conjugated proteins and peptides	US	Granted: 4th year fee due 02-18-2020	ABZENA (UK) LIMITED BABRAHAM RESEARCH CAMPUS BABRAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US14659598	2015-03-16	US9415113B2	2016-08-16			GB0903746	2009-03-04	

TRADEMARK
REEL: 006721 FRAME: 0456

Technology Name	Title	Authority	Legal Status (Standardized)	Current Assignee	Application Number	Application/ Filing Date	Publication Number	Publication Date	Holder of Unreleased Licenses	Notes/Chain of Title Issues	Priority Number(s)	Priority Date(s)	Child Cases
ABZ04 WO2005007197	Conjugated biological molecules and their preparation	US	Granted: 4th year fee due 03-13-2020	ABZENA (UK) LIMITED THE LONDON BIOTECHNOLOGY INNOVATION CENTRE, 2 ROYAL COLLEGE STREET, CAMDEN LONDON, UNITED KINGDOM NW1 0TU	US14444859	2014-07-28	US9439974B2	2016-09-13			GB0316294	2003-07-11	
ABZ18 WO2014064423 (A1)	Drug-Protein Conjugates	US	Pending	ABZENA (UK) LIMITED BARBARAHAM RESEARCH CAMPUS BARBARAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US14437537	2013-10-11	US20150290342A1	2015-10-15			US61717743	2012-10-24	
ABZ11 WO2010010324 (A1) To be abandoned in due course	Novel Reagents and Method for Conjugating Biological Molecules	US	Granted: 4th year fee due 08-20-2021	ABZENA (UK) LIMITED BARBARAHAM RESEARCH CAMPUS BARBARAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US14086702	2013-11-21	US20140081047A1	2014-03-20			GB0813339	2008-07-21	
ABZ11 to be abandoned in due course	Reagents and method for conjugating biological molecules	US	Granted: 4th year fee due 08-20-2021	ABZENA (UK) LIMITED BARBARAHAM RESEARCH CAMPUS, BARBARAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US14086702	2013-11-21	US9896412B2	2018-02-20			GB0813339	2008-07-21	
ABZ16 granted US only	Novel Conjugation Reagents	US	Granted: 4th year fee due 11-16-2020	ABZENA (UK) LIMITED THE LONDON BIOTECHNOLOGY INNOVATION CENTRE, 2 ROYAL COLLEGE STREET, CAMDEN LONDON, UNITED KINGDOM NW1 0TU	US13919217	2013-06-17	US965031B2	2017-05-16			US61661300	2012-06-18	US15482033

Technology Name	Title	Authority	Legal Status (Standardized)	Current Assignee	Application Number	Application/ Filing Date	Publication Number	Publication Date	Holder of Unreleased Claims	Notes/Chain of Title Issues	Priority Number(s)	Priority Date(s)	Child Cases
ABZ24 To be Abandoned	Conjugated Blood Coagulation Factor VIIA	US	Granted: 4th year fee due 10-15-2019	ABZENA (UK) LIMITED BARBRAHAM RESEARCH CAMPUS BARBRAHAM CAMBRIDGE, UNITED KINGDOM CB22 3AT	US13645304	2011-04-28	US9309507B2	2016-04-12			GB1007336	2010-04-30	
ABZ11 To be abandoned in the course	Novel Reagents and Method for Conjugating Biological Molecules	US	Granted: 8th year fee due 06-30-2021	ABZENA (UK) LIMITED THE LONDON BIOTECHNOLOGY INNOVATION CENTRE, 2 ROYAL COLLEGE STREET, CAMDEN LONDON, UNITED KINGDOM NW1 0TU	US13175820	2011-07-01	US8618333B2	2013-12-31		No Assignment Recorded: Parent Assignment is OK	GB0813339	2008-07-21	US14086702
ABZ04 WO2005007197	Conjugated biological molecules and their preparation	US	Granted: 8th year fee due 02-28-2022	ABZENA (UK) LIMITED THE LONDON BIOTECHNOLOGY INNOVATION CENTRE, 2 ROYAL COLLEGE STREET, CAMDEN LONDON, UNITED KINGDOM NW1 0TU	US13077980	2011-03-31	US8816051B2	2014-08-26			GB0316294	2003-07-11	US14444859
ABZ04 WO2005007197	Conjugated biological molecules and their preparation	US	Granted: 12th year fee due 11-10-2022	ABZENA (UK) LIMITED 90 FETTER LANE LONDON, UNITED KINGDOM EC4A 1JP	US12458931	2009-07-28	US7939630B2	2011-05-10		No Assignment Recorded: Parent Assignment is OK	GB0316294	2003-07-11	US13077980 US14444859
ABZ04 WO2005007197	Conjugated biological molecules and their preparation	US	Granted: 12th year fee due 03-29-2021	ABZENA (UK) LIMITED 90 FETTER LANE LONDON, UNITED KINGDOM EC4A 1JP	US10564340	2004-07-12	US7595292B2	2009-09-29			GB0316294	2003-07-11	US12458931 US13077980 US14444859

TRADEMARK

REEL: 006721 FRAME: 0458

Technology Name	Title	Authority	Legal Status (Standardized)	Current Assignee	Application Number	Application/ Filing Date	Publication Number	Publication Date	Holder of Unreleased Licenses	Notes/Chain of Title Issues	Priority Number(s)	Priority Date(s)	Child Cases
ABZ02	Uniform molecular weight polymers	US	Granted: No fees due	ABZENA (UK) LIMITED	US10070318	2002-08-09	US6803438B1	2004-10-12			EP99307152	1999-09-08	

Abzena (Cambridge) Limited

Technology Name	Title	Authority	Legal Status (Standardized)	Current Assignee	Application Number	Application/ Filing Date	Publication Number	Publication Date	Holder of Unreleased Licenses	Notes/Chain of Title Issues	Priority Number(s)	Priority Date(s)	Child Cases
ABZ05	Methods of studying tolerance in MHC-II transgenic animals	US	Granted	ABZENA (CAMBRIDGE) LIMITED	US11719876	2007-05-22	US9648857B2	2017-05-16			GB0425713.5	2004-11-23	
ABZ06	Composite Human antibodies (Method of humanising antibodies)	US	Pending	ABZENA (CAMBRIDGE) LIMITED	US15471290	2017-03-28	US20170210820A1	2017-07-27			0502201.7	2005-02-03	
ABZ14 CD52	Humanised anti CD52 antibodies	US	Granted	ABZENA (CAMBRIDGE) LIMITED	US14123349	2014-01-14	US9321841B2	2016-04-26			GB1109238.4	2011-06-01	

TRADEMARK

REEL: 006721 FRAME: 0460

Technology Name	Title	Authority	Legal Status (Standardized)	Current Assignee	Application Number	Application/ Filing Date	Publication Number	Publication Date	Holder of Unreleased Claims	Notes/Chart of Title Issues	Priority Number(s)	Priority Date(s)	Child Cases
ABZ13 CTLA-4	Humanised anti CTLA-4 antibodies	US	Granted	ABZENA (CAMBRIDGE) LIMITED	US14003900	2013-12-18	US9714290B2	2017-07-25			GB1103955.9	2011-03-09	

EXHIBIT C

Trademarks

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Items	TTAB Informa- tion
Episcreen	U.S. Federal	REGISTERED	(INT. CL. 5) PHARMACEUTICALS AND PHARMACEUTICAL PREPARATIONS USED TO TREAT CANCER, DISEASES AND DISORDERS OF THE IMMUNE SYSTEM, VIRAL DISEASES AND DISORDERS, INFLAMMATORY DISEASES, FIBROTIC DISEASES, PULMONARY DISEASES, GASTRO-INTESTINAL DISEASES AND DISORDERS, HAEMATOLOGICAL DISEASES AND DISORDERS, NEUROLOGICAL DISEASES AND DISORDERS, PAIN, OBESITY, DIABETES AND GRAFT REJECTION; CHEMICAL PREPARATIONS FOR MEDICAL OR PHARMACEUTICAL PURPOSES, NAMELY, CHEMICALS SOLD AS INTEGRAL COMPONENT PARTS OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER, DISEASES AND DISORDERS OF THE IMMUNE SYSTEM, VIRAL DISEASES AND DISORDERS, INFLAMMATORY DISEASES, FIBROTIC DISEASES, PULMONARY DISEASES, GASTRO-INTESTINAL DISEASES AND DISORDERS, HAEMATOLOGICAL DISEASES AND DISORDERS, NEUROLOGICAL DISEASES AND DISORDERS, PAIN, OBESITY, DIABETES AND GRAFT REJECTION; CHEMICO-PHARMACEUTICAL PREPARATIONS, NAMELY, PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER, DISEASES AND DISORDERS OF THE	ABZENA (UK) LIMITED UNITED KINGDOM BABRAHAM RESEARCH COMPANY CAMPUS BABRAHAM CAMBRIDGE CB223AT GB (UNITED KINGDOM)	86716415	6-Aug-15	5093688	6-Dec-16		

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Lens	TTAB Informa- tion
			<p>IMMUNE SYSTEM, VIRAL DISEASES AND DISORDERS, INFLAMMATORY DISEASES, FIBROTIC DISEASES, PULMONARY DISEASES, GASTRO-INTESTINAL DISEASES AND DISORDERS, HAEMATOLOGICAL DISEASES AND DISORDERS, NEUROLOGICAL DISEASES AND DISORDERS, PAIN, OBESITY, DIABETES AND GRAFT REJECTION; VACCINES; PHARMACEUTICAL PREPARATIONS FOR SKIN CARE (INT. CL. 42) SCIENTIFIC RESEARCH AND PRODUCT DEVELOPMENT SERVICES IN RELATION TO PHARMACEUTICAL AND MEDICAL PRODUCTS; PHARMACEUTICAL RESEARCH SERVICES; PHARMACEUTICAL PRODUCT EVALUATION; TESTING OF PHARMACEUTICALS, NAMELY, ASSESSING THE POTENTIAL IMMUNOGENICITY OF PROTEINS AND ANTIBODIES BY MEASURING IMMUNE CELL RESPONSES TO THE PHARMACEUTICAL; PHARMACEUTICAL DRUG DEVELOPMENT SERVICES; DEVELOPMENT OF PHARMACEUTICAL PREPARATIONS AND MEDICINES; PROVIDING MEDICAL AND SCIENTIFIC RESEARCH INFORMATION IN THE FIELD OF PHARMACEUTICALS AND CLINICAL TRIALS; PROVISION OF SCIENTIFIC INFORMATION IN THE FIELDS OF CANCER, DISEASES AND DISORDERS OF THE IMMUNE SYSTEM, VIRAL DISEASES AND DISORDERS, INFLAMMATORY DISEASES, FIBROTIC DISEASES, PULMONARY DISEASES, GASTRO-INTESTINAL DISEASES AND DISORDERS, HAEMATOLOGICAL</p>							

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Leads	TTAB Informa- tion
Abzerna	U.S. Federal	REGISTERED	DISEASES AND DISORDERS, NEUROLOGICAL DISEASES AND DISORDERS, PAIN, OBESITY, DIABETES AND GRAFT REJECTION; TOXICOLOGY SERVICES; PROVISION OF SCIENTIFIC INFORMATION RELATING TO THE CHEMICAL INDUSTRY, NAMELY, INFORMATION ON THE SUBJECT OF CHEMICAL PRODUCT DEVELOPMENT (INT. CL. 44) MEDICAL SERVICES, NAMELY, PROVIDING MEDICAL INFORMATION REGARDING PHARMACEUTICALS; PHARMACY AND HEALTH ADVICE; PHARMACEUTICAL SERVICES AND PROVISION OF PHARMACEUTICAL INFORMATION, ALL IN THE NATURE OF PROVIDING MEDICAL INFORMATION REGARDING PHARMACEUTICALS; MEDICAL SCREENING; MEDICAL SCREENING TO ASSESS THE POTENTIAL IMMUNOGENICITY OF THERAPEUTIC ANTIBODIES AND PROTEINS	POLYETHERICS LTD. UNITED KINGDOM LIMITED COMPANY LONDON BIOSCIENCE INNOVATION CENTRE 2 ROYAL COLLEGE ST LONDON NW10NH GB (UNITED KINGDOM)	86234440	27-Mar-14	4737716	19-May-15		

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Leads	TTAB Informa- tion
			<p>(INT. CL. 5) PHARMACEUTICALS, PHARMACEUTICAL COMPOSITIONS, AND PHARMACEUTICAL PREPARATIONS, USED TO TREAT CANCER, DISEASES OF THE IMMUNE SYSTEM, VIRAL INFECTIONS, HIV, INFLUENZA, INFLAMMATORY DISEASES, PULMONARY DISEASES, BLOOD DISORDERS, NEURODEGENERATIVE DISEASES, GRAFT REJECTION; CHEMICAL PREPARATIONS FOR MEDICAL OR PHARMACEUTICAL PURPOSES, NAMELY, CHEMICALS SOLD AS INTEGRAL COMPONENT PARTS OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER, DISEASES OF THE IMMUNE SYSTEM, VIRAL INFECTIONS, HIV, INFLUENZA, INFLAMMATORY DISEASES, FIBROTIC DISEASES, PULMONARY DISEASES, BLOOD DISORDERS, NEURODEGENERATIVE DISEASES, GRAFT REJECTION; CHEMICO-PHARMACEUTICAL PREPARATIONS, NAMELY, PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER, DISEASES OF THE IMMUNE SYSTEM, VIRAL INFECTIONS, HIV, INFLUENZA, INFLAMMATORY DISEASES, FIBROTIC DISEASES, PULMONARY DISEASES, BLOOD DISORDERS, NEURODEGENERATIVE DISEASES, GRAFT REJECTION (INT. CL. 42) SCIENTIFIC RESEARCH AND PRODUCT DEVELOPMENT SERVICES IN RELATION TO PHARMACEUTICAL AND MEDICAL PRODUCTS.</p>							

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Leads	TTAB Informa- tion
			<p>SCIENTIFIC SERVICES, NAMELY, PRODUCT DEVELOPMENT IN THE FIELD OF PHARMACEUTICALS; RESEARCH, NAMELY, SCIENTIFIC RESEARCH AND PRODUCT DEVELOPMENT IN THE FIELD OF PHARMACEUTICALS; INDUSTRIAL RESEARCH IN THE FIELD OF PHARMACEUTICALS; PRODUCT DESIGN IN THE FIELD OF PHARMACEUTICALS; PHARMACEUTICAL RESEARCH SERVICES; PHARMACEUTICAL PRODUCT EVALUATION; TESTING OF PHARMACEUTICALS; PHARMACEUTICAL DRUG DEVELOPMENT SERVICES; DEVELOPMENT OF PHARMACEUTICAL PREPARATIONS AND MEDICINES; PROVIDING MEDICAL AND SCIENTIFIC RESEARCH INFORMATION IN THE FIELD OF PHARMACEUTICALS; PROVISION OF SCIENTIFIC INFORMATION IN THE FIELDS OF CANCER, DISEASES OF THE IMMUNE SYSTEM, VIRAL INFECTIONS, HIV, INFLUENZA, INFLAMMATORY DISEASES, FIBROTIC DISEASES, PULMONARY DISEASES, BLOOD DISORDERS, NEURODEGENERATIVE DISEASES, GRAFT REJECTION; PROVIDING OF SCIENTIFIC INFORMATION REGARDING PHARMACEUTICALS AND MEDICINES; PROVISION OF SCIENTIFIC INFORMATION RELATING TO THE CHEMICAL INDUSTRY, NAMELY, INFORMATION ON THE SUBJECT OF CHEMICAL PRODUCT DEVELOPMENT (INT. CL. 44) MEDICAL SERVICES, NAMELY, PROVIDING MEDICAL INFORMATION REGARDING PHARMACEUTICALS;</p>							

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Lens	TTAB Informa- tion
ThioBridge	U.S. Federal	REGISTERED	PHARMACEUTICAL SERVICES AND PROVISION OF PHARMACEUTICAL INFORMATION; ALL IN THE NATURE OF PROVIDING MEDICAL INFORMATION REGARDING PHARMACEUTICALS; PROVIDING TO OTHERS A COLLECTION OF INFORMATION; NAMELY, PROVIDING MEDICAL INFORMATION RELATING TO THE USE OF PHARMACEUTICALS	ABZENA (UK) LIMITED UNITED KINGDOM COMPANY THE LONDON BIOSCIENCE INNOVATION CENTRE 2 ROYAL COLLEGE STREET CAMDEN, LONDON NW10NH GB (UNITED KINGDOM)	85775260	8-Nov-12	4860075	24-Nov-15		
			(INT. CL. 1) (BASED ON USE IN COMMERCE) CHEMICAL PREPARATIONS FOR USE AS PHARMACEUTICAL INTERMEDIATES; CHEMICAL PREPARATIONS FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS; DIAGNOSTIC REAGENTS FOR SCIENTIFIC USE; REAGENTS FOR SCIENTIFIC PURPOSES (INT. CL. 5) (BASED ON USE IN COMMERCE) PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR THE TREATMENT OF VIRAL DISEASES AND DISORDERS, NEUROLOGICAL DISEASES AND DISORDERS, IMMUNE DISEASES AND DISORDERS, RESPIRATORY DISEASES AND DISORDERS, MICROBIAL INFECTIONS AND DISEASES, CANCER, HAEMATOLOGICAL DISEASES AND DISORDERS, GASTRO-INTESTINAL DISEASES AND DISORDERS, INFLAMMATION, ARTHRITIS, HEPATITIS, ANEMIA, COAGULATION DISEASES AND DISORDERS, PAIN, OBESITY, AND DIABETES; CHEMICAL PREPARATIONS FOR MEDICAL USE, NAMELY, PEPTIDE AND PROTEIN AGENTS; DIAGNOSTIC REAGENTS FOR MEDICAL USE							

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Lens	TTAB Informa- tion
CHEMO ASSEMBLY	U.S. Federal	REGISTERED	(INT. CL. 45) RENTAL AND LICENSING OF INTELLECTUAL PROPERTY RELATING TO PHARMACEUTICAL PREPARATIONS AND SUBSTANCES AND CHEMICAL PREPARATIONS FOR MEDICAL USE, CHEMICAL PREPARATIONS AND SUBSTANCES FOR USE AS PHARMACEUTICAL INTERMEDIATES AND CHEMICAL PRODUCTS FOR USE IN PHARMACEUTICALS	ABZENA (UK) LIMITED UNITED KINGDOM COMPANY THE LONDON BIOSCIENCE INNOVATION CENTRE 2 ROYAL COLLEGE STREET CAMDEN, LONDON NW10NH GB (UNITED KINGDOM)	85614091	2-May-12	4438343	26-Nov-13		
TheraPEG	U.S. Federal	REGISTERED	(INT. CL. 1) CHEMICAL PREPARATIONS FOR USE AS PHARMACEUTICAL INTERMEDIATES; CHEMICAL PREPARATIONS FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS (INT. CL. 5) PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR THE TREATMENT OF VIRAL DISEASES AND DISORDERS, NEUROLOGICAL DISEASES AND DISORDERS, CANCER, HAEMATOLOGICAL DISEASES AND DISORDERS, GASTRO-INTESTINAL DISEASES AND DISORDERS, INFLAMMATION, ARTHRITIS, HEPATITIS, ANAEMIA, COAGULATION DISEASES AND DISORDERS, PAIN, OBESITY, AND DIABETES; CHEMICAL PREPARATIONS FOR MEDICAL USE, NAMELY, PEPTIDE AND PROTEIN AGENTS (INT. CL. 42) PHARMACEUTICAL RESEARCH SERVICES; BIOMEDICAL RESEARCH SERVICES; CHEMICAL RESEARCH SERVICES; DEVELOPMENT OF PHARMACEUTICAL	ABZENA (UK) LIMITED UNITED KINGDOM COMPANY BABRAHAM RESEARCH CAMPUS BABRAHAM, CAMBRIDGE CB223AT GB (UNITED KINGDOM)	77833175	23-Sep-09	3949768	26-Apr-11		

Trademark	Database	Status	Goods/Services	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Un-released Liens	TTAB Information
			PREPARATIONS AND MEDICINES; CHEMICAL LABORATORY SERVICES [MEDICAL LABORATORY SERVICES] (INT. CL. 45) RENTAL AND LICENSING OF INTELLECTUAL PROPERTY							

EXHIBIT D

Mask Works

None.